Pal-AHK Limited Evidence

What It Is

Pal-AHK is the palmitoylated form of the tripeptide L-alanyl-L-histidyl-L-lysine (AHK) — three amino acids (Ala–His–Lys) covalently joined to palmitic acid, a sixteen-carbon saturated fatty acid, via an amide bond at the N-terminal alanine. The palmitoyl moiety substantially increases the molecule's lipophilicity, shifting the otherwise hydrophilic tripeptide into a form that can partition into the stratum corneum lipid lamellae and reach viable epidermal and upper dermal layers when applied topically. The resulting molecule has a calculated molecular weight of approximately 592 daltons and is supplied by cosmetic raw-material houses as an off-white powder, typically pre-solubilized in a propylene glycol or caprylic/capric triglyceride carrier for ease of incorporation into finished formulations.

The AHK sequence itself was identified by Loren Pickart and colleagues during the same broad program of work that produced the better-known glycyl-L-histidyl-L-lysine (GHK) tripeptide isolated from human plasma in 1973 (PMID 4356974). GHK and AHK differ by a single amino acid at position one — glycine versus alanine — and both share the central histidine and C-terminal lysine that form the copper-binding triangle of the GHK-Cu and AHK-Cu complexes. The biological history of these tripeptides has been driven primarily by the copper complexes: GHK-Cu became one of the most studied "matrikine" peptides in cosmetic dermatology, and AHK-Cu was characterized in 2007 by Pyo and colleagues at Seoul National University as a stimulator of human dermal papilla cells and ex-vivo human hair follicle elongation (PMID 17703734).

Pal-AHK is a cosmetic-industry derivative of that lineage. Whereas AHK-Cu carries the copper(II) ion that the literature consistently identifies as a key driver of the complex's biological activity, Pal-AHK is the copper-free tripeptide carried instead on a fatty-acid tail. The rationale for the substitution is straightforward: copper-peptide complexes are blue-green, can stain formulations and skin, oxidize ascorbic acid and thiol antioxidants on contact, and create incompatibilities with common cosmetic excipients including silicones, emulsifiers with chelating impurities, and reduced-form vitamins. Palmitoylation removes those handling problems while preserving the AHK amino-acid sequence that suppliers cite as the receptor-binding "address" of the molecule.

The trade-off, which is rarely surfaced clearly in supplier marketing, is that the bulk of the mechanistic and bioactivity evidence cited in support of Pal-AHK was generated using AHK-Cu — the copper-bound form. Whether a copper-free, palmitoyl-conjugated AHK retains the same hair-follicle dermal papilla cell stimulation, the same VEGF-induction profile, or the same anti-apoptotic effect as AHK-Cu is an empirical question that has not been answered in the indexed literature. Suppliers typically argue that the AHK sequence is the active pharmacophore and that the lipidated free peptide retains some subset of the receptor-level effects, but independent in-vitro head-to-head comparisons of AHK-Cu versus Pal-AHK at matched concentrations are not available in PubMed-indexed publications. This is the single most important caveat for interpreting cosmetic marketing copy that cites the Pyo 2007 study or the broader copper-peptide body of work as evidence for a Pal-AHK serum.

Within the cosmetic INCI-naming framework, the "palmitoyl tripeptide" family is fragmented and confusing. Palmitoyl Tripeptide-1 corresponds to palmitoyl-Gly-His-Lys (Pal-GHK), the lipidated form of GHK and the central active in the Sederma trade-name product Matrixyl. Palmitoyl Tripeptide-3 and Palmitoyl Tripeptide-5 are different sequences entirely (both based on the GPR/GPQ collagen-derived motif). The non-copper lipidated AHK does not have a uniformly assigned, universally recognized INCI number — different suppliers have used different naming conventions, and some products marketed as containing "palmitoyl AHK" or "palmitoyl tripeptide-AHK" are sold under proprietary trade names without standardized INCI registration. This naming ambiguity contributes to consumer and formulator confusion about which lipidated tripeptide is actually present in any given finished product.

Mechanism of Action

The mechanistic claims attached to Pal-AHK are extrapolated almost entirely from the AHK-Cu literature combined with the general pharmacology of palmitoyl peptide skin-penetration enhancement. Direct receptor- or pathway-level studies of the non-copper, lipidated form are not available in indexed literature. The summary below clearly distinguishes what is established for the AHK sequence (in its copper-bound form) from what is claimed but unproven for Pal-AHK specifically.

• Claimed dermal papilla cell stimulation — The central mechanistic claim for the AHK sequence comes from Pyo et al. 2007 (PMID 17703734), in which AHK-Cu²⁺ at picomolar to nanomolar concentrations (10⁻¹² to 10⁻⁹ M) stimulated proliferation of cultured human dermal papilla cells (DPCs) and elongation of ex-vivo human hair follicles in organ culture. Dermal papilla cells are the specialized mesenchyme-derived fibroblasts at the base of each hair follicle that regulate cycling between anagen (growth), catagen (regression), and telogen (rest) phases. The copper-bound complex was the agent tested in that study; whether the copper-free palmitoylated form reproduces the same DPC effect is an open empirical question.
• Claimed VEGF / angiogenic signaling — In dermal-fibroblast and dermal-papilla-cell models, AHK-Cu (and the chemically related GHK-Cu) increased expression of vascular endothelial growth factor (VEGF), the master regulator of angiogenesis (Pyo 2007; Pickart 2008 GHK tissue-remodeling review). In the hair-growth context, increased perifollicular blood flow and capillary density are mechanistically plausible as supports of anagen-phase hair shaft production. Without copper, the AHK sequence's affinity for the relevant transcription-factor and growth-factor signaling components is poorly characterized.
• Claimed perifollicular dermal sheath / fibroblast activation — The copper-tripeptide literature consistently reports stimulation of dermal fibroblast proliferation and extracellular matrix protein synthesis (collagen I and III, glycosaminoglycans, fibronectin). For Pal-AHK in a hair-growth or skin-firming positioning, suppliers extrapolate this fibroblast activation to the perifollicular dermal sheath and to the dermal collagen network underlying the epidermis.
• Anti-apoptotic claim — Pyo 2007 reported that AHK-Cu reduced apoptosis of dermal papilla cells under the conditions tested. The broader copper-peptide literature has documented anti-apoptotic effects in dermal fibroblasts and other cell types, attributed to copper-dependent superoxide dismutase activity and to direct modulation of pro-apoptotic gene expression. Without copper, neither the antioxidant nor the gene-expression mechanism translates straightforwardly.
• Palmitoyl moiety enhances stratum corneum penetration — This is the one mechanism that is empirically established for Pal-AHK as a chemical entity. Lipid-conjugated peptides (palmitoyl, myristoyl, oleoyl) have substantially greater partition coefficients into the stratum corneum than their parent water-soluble peptides. Schagen 2017 (Cosmetics 4:16) and Lupo & Cole 2007 (PMID 18045359) both review the rationale: the palmitoyl chain inserts into intercellular lipid lamellae, the peptide head-group then diffuses into the viable epidermis, and intracellular esterases progressively hydrolyze the amide bond to release free peptide and palmitic acid. In-vitro Franz-cell studies of related palmitoyl tripeptides have confirmed measurable epidermal and upper-dermal accumulation; comparable Franz-cell data specifically for Pal-AHK is not indexed.
• Signal-peptide framework — In the cosmetic-peptide taxonomy of Lupo & Cole 2007 (PMID 18045359), peptides are classified as signal peptides (mimicking matrix-degradation fragments to trigger collagen and elastin synthesis), neurotransmitter-affecting peptides (botulinum-toxin-mimetic), or carrier peptides (delivering trace metals such as copper). Pal-AHK is positioned by suppliers as a signal peptide — the AHK sequence supposedly acts as a fragment-derived "address" recognized by surface or intracellular signaling complexes. The carrier-peptide identity (delivering Cu²⁺) that defines AHK-Cu is, by construction, absent in the non-copper lipidated form.
• Caveat: copper is doing most of the work in the AHK-Cu literature — A consistent finding across the GHK-Cu and AHK-Cu mechanistic literature is that copper(II) is not an inert spectator. The copper ion participates directly in superoxide dismutase activity, in the redox-active gene-expression effects documented in the Pickart & Margolina 2018 transcriptomic work (PMID 29986520), and in the structural conformation that supports binding to relevant cell-surface receptors. Stripping copper out of the molecule does not necessarily preserve the bioactivity profile — it may preserve only the subset of effects mediated by the peptide backbone alone, which is poorly characterized.
• Practical formulation note — Pal-AHK is typically incorporated at 0.5–2% of a finished cosmetic formulation. At those concentrations, the peptide is not delivering pharmacologic doses of any active — even if 100% of the applied peptide reached the dermal papilla cell, the local concentration would sit in the picomolar-to-nanomolar range that Pyo 2007 documented as effective for AHK-Cu. The formulation arithmetic supports the plausibility of dose, but does not substitute for direct evidence of activity for the lipidated free peptide.

What the Research Shows

The published evidence base for Pal-AHK as a stand-alone cosmetic active is, to be direct, sparse to non-existent in the peer-reviewed indexed literature. The mechanistic and efficacy claims that appear in supplier and brand marketing materials are extrapolated from three adjacent bodies of work: (1) the AHK-Cu hair-follicle literature centered on Pyo 2007; (2) the GHK / GHK-Cu dermatology and tissue-remodeling literature reviewed by Pickart and Margolina; and (3) the general cosmetic-peptide skin-penetration and signal-peptide literature reviewed by Schagen, Lupo & Cole, and others.

• Pyo 2007 — AHK-Cu on human hair follicles (PMID 17703734) — The single most-cited primary study for the AHK sequence in any hair-growth context. Cultured human dermal papilla cells were exposed to L-alanyl-L-histidyl-L-lysine-Cu²⁺ at concentrations from 10⁻¹² to 10⁻⁹ M; statistically significant proliferation increase and reduction in apoptosis. Ex-vivo human hair-follicle organ cultures showed increased follicle elongation. Mechanistic readouts included VEGF upregulation and TGF-β1 modulation. Limitation: this is in-vitro / ex-vivo only; the agent tested was the copper-bound complex, not Pal-AHK; no clinical hair-count or hair-density data; single laboratory.
• Pickart 2008 — GHK and tissue remodeling (J Biomater Sci Polym Ed) — Comprehensive review of the GHK / GHK-Cu literature with brief reference to the broader tripeptide-copper family. Describes wound healing, hair-transplant survival improvements, and gene-expression effects. Establishes the framework within which the AHK literature is interpreted but does not provide independent Pal-AHK evidence.
• Pickart & Margolina 2018 — GHK-Cu transcriptomics (PMID 29986520) — Transcriptome analysis of GHK and GHK-Cu effects on human gene expression. Documents broad effects on wound-healing, anti-inflammatory, and antioxidant gene programs. Frequently cited by Pal-AHK marketing as evidence for "gene modulation" claims; the underlying data is for GHK / GHK-Cu, not for AHK or Pal-AHK.
• Pickart 2012 — GHK-Cu and oxidative stress / cognitive aging (PMID 22666519) — Review of the human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Provides historical context for the tripeptide-copper class; not directly applicable to Pal-AHK.
• Lupo & Cole 2007 — Cosmeceutical peptides review (PMID 18045359) — Categorizes cosmetic peptides into signal, neurotransmitter-affecting, and carrier classes. Frames the rationale for palmitoylation as a delivery strategy. Does not directly evaluate Pal-AHK.
• Schagen 2017 — Topical peptide treatments (Cosmetics 4:16) — Open-access review of cosmetic peptides covering pal-KTTKS, palmitoyl tripeptide-1 / -3 / -5, palmitoyl-β-Ala-His, and others. Describes a 60-volunteer 84-day study in which palmitoyl tripeptide-3/5 outperformed placebo and pal-KTTKS for anti-wrinkle endpoints. Does not include data specific to a non-copper Pal-AHK product.
• Robinson 2005 — pal-KTTKS RCT (PMID 18492182) — A 12-week double-blind placebo-controlled split-face study of 93 women applying 3 ppm pal-KTTKS in moisturizer. Significant improvement in fine lines and wrinkles versus moisturizer alone. Cited here as the methodological template for what a real palmitoyl-peptide cosmetic RCT looks like — a template that has not been applied to non-copper Pal-AHK.
• Choi 2014 — KTTKS / pal-KTTKS skin permeation (PMID 25143811) — Dermal stability and in-vitro skin permeation comparison of free KTTKS versus palmitoyl-KTTKS. Confirms that palmitoylation increases skin permeation and dermal stability of the parent peptide. Mechanistically informative for the palmitoyl peptide class as a whole.
• Cosmetic peptide reviews 2020–2024 — More recent reviews of the cosmetic peptide field (PMID 34957891 anti-ageing peptide review; PMID 34451799 synthetic peptides in cosmetics for sensitive skin) catalogue the palmitoyl tripeptide family on INCI lists of marketed products; the non-copper Pal-AHK does not appear as a separately reviewed entity in any major peer-reviewed cosmetic-dermatology review through 2024.
• Manufacturer / supplier in-house data — Several cosmetic raw-material suppliers provide in-house in-vitro proliferation assays, ex-vivo skin equivalent collagen-synthesis assays, or finished-product hair-density photometric studies for products containing Pal-AHK. These data are not peer-reviewed, are typically conducted on the finished multi-ingredient formulation rather than on Pal-AHK in isolation, and should be evaluated as marketing literature, not as clinical evidence.

Human Data

There are essentially zero peer-reviewed clinical randomized controlled trials of non-copper Pal-AHK as a stand-alone topical agent in the indexed literature. The published "human data" attached to Pal-AHK marketing falls into three categories, none of which constitute clinical evidence in the regulatory sense applied to drug development:

• Ex-vivo human tissue data (AHK-Cu, not Pal-AHK) — Pyo et al. 2007 (PMID 17703734) used cultured human dermal papilla cells and ex-vivo human hair-follicle organ cultures from scalp biopsy explants. This is human-derived tissue, but is not a clinical trial; the agent was AHK-Cu²⁺, not the lipidated free peptide.
• Adjacent compound clinical trials — Robinson et al. 2005 (PMID 18492182) is the closest published methodological analog: a 12-week double-blind placebo-controlled split-face RCT of pal-KTTKS in moisturizer in 93 women, demonstrating quantitative wrinkle-reduction superiority versus vehicle. Schagen 2017 cites a 60-volunteer 84-day controlled study of palmitoyl tripeptide-3/5 in which the lipidated tripeptide outperformed placebo and pal-KTTKS. Neither study tested Pal-AHK.
• Manufacturer-funded finished-product hair-growth studies — Several cosmetic brands have commissioned uncontrolled or single-arm photometric hair-density and hair-count studies on multi-ingredient hair serums containing Pal-AHK alongside other actives (caffeine, niacinamide, biotin, redensyl-class compounds, copper peptides, plant extracts). These studies generally are not registered on ClinicalTrials.gov, are not published in peer-reviewed indexed journals, and cannot isolate the contribution of Pal-AHK from the rest of the formulation. They function as marketing collateral, not as evidence of Pal-AHK efficacy.

For category context, the broader topical-peptide RCT base that exists for compounds in the same family — pal-KTTKS (Robinson 2005, PMID 18492182), palmitoyl tripeptide-3/5 (Schagen 2017 review), GHK-Cu in wound-healing and hair-transplant adjunct contexts (Pickart 2008 J Biomater Sci Polym Ed), and the broader cosmetic-peptide reviews by Lupo & Cole 2007 (PMID 18045359), the synthetic-peptide cosmetics review (PMID 34451799), and the Pickart & Margolina 2018 GHK-Cu transcriptomics paper (PMID 29986520) — illustrates that well-designed placebo-controlled topical-peptide RCTs are feasible, are sometimes done, and typically yield modest but statistically detectable wrinkle, firmness, or hair-density improvements when the underlying active and vehicle are well-characterized. The absence of such a study for Pal-AHK is notable. It is not evidence that Pal-AHK does not work; it is evidence that the manufacturers selling it have not invested in the kind of trial that would tell us whether it does.

From the regulatory perspective, this evidence gap is unsurprising. Pal-AHK is sold as a cosmetic ingredient, not as a drug, and the U.S. cosmetic regulatory framework does not require demonstration of efficacy. Manufacturers can make "structure / function" cosmetic claims (improves the appearance of, supports, helps maintain) without controlled clinical data. The economic incentive to invest in a peer-reviewed RCT is therefore minimal, and the resulting evidence base is what it is — adequate for cosmetic marketing, inadequate for clinical claims.

Dosing from the Literature

Pal-AHK is a topical cosmetic ingredient with no parenteral, oral, or systemic dosing role. The "dosing" question reduces to the formulation-percentage at which Pal-AHK is incorporated into a finished serum, cream, or scalp tonic, and the application frequency the consumer follows.

Reconstitution & Storage

Pal-AHK is supplied to formulators as a raw cosmetic ingredient — typically a powder or pre-solubilized concentrate — and is not reconstituted in the way that lyophilized injectable peptides are. The handling guidance below reflects the chemistry of the lipidated tripeptide rather than parenteral reconstitution.

• Storage of raw material — Sealed powder or concentrate stored at 2–8°C protected from light and moisture. Shelf life of 24–36 months when stored per supplier specification. Allow to equilibrate to room temperature before opening to prevent moisture condensation on cold powder.
• pH window — Pal-AHK is most stable in mildly acidic to neutral aqueous formulations (pH 5.0–7.0). Strongly alkaline conditions (pH > 8) accelerate amide bond hydrolysis and can liberate free palmitic acid and free AHK tripeptide, which is then susceptible to enzymatic degradation by skin proteases.
• Compatibility — Compatible with most common cosmetic excipients including glycerin, hyaluronic acid, niacinamide, panthenol, allantoin, plant extracts, and standard preservative systems. Avoid co-formulation with strong oxidizers (high-percentage benzoyl peroxide, high-concentration ascorbic acid in water above pH 3.5 — note: this is the inverse of the AHK-Cu copper-vitamin C incompatibility, which arises from copper-catalyzed ascorbate oxidation; Pal-AHK without copper is more flexible here).
• Temperature limits — Avoid exposure to heating above 60°C during formulation. Add Pal-AHK to the cool-down phase of an emulsion after the temperature has dropped below 50°C.
• Finished-product shelf life — Finished serums and creams containing Pal-AHK at 0.5–2% typically carry 12–24 month shelf lives at controlled room temperature with appropriate preservation. Refrigeration after opening is not required but extends finished-product stability.
• Inspection — Powder should be off-white to pale ivory and free-flowing; pre-solubilized concentrates should be clear to slightly hazy. Discard if discolored brown or yellow, if odor changes from neutral to rancid (a sign of palmitate oxidation), or if visible particulate appears in a previously clear concentrate.

→ Use the Kalios Dosing Calculator for cosmetic-formulation conversions

Side Effects & Risks

The published safety record of palmitoyl peptides as a class is favorable; sensitization and irritation are rare at cosmetic-use concentrations, and no systemic safety concerns have surfaced in decades of use of pal-KTTKS, palmitoyl tripeptide-1 (Pal-GHK / Matrixyl), and related lipidated tripeptides. Pal-AHK specifically has minimal published independent safety data, and the safety read should be conditioned on the broader palmitoyl-peptide class.

• Contact sensitization — Rare at the 0.5–2% topical concentrations used in finished products. The Cosmetic Ingredient Review (CIR) safety assessment of palmitoyl oligopeptides as a class did not identify substantive irritation or sensitization signals in the published literature. Predisposed individuals (atopic dermatitis, prior peptide allergy, multiple cosmetic contact allergies) should patch-test before broad application.
• Comedogenicity — Palmitic acid and palmitate-conjugated molecules can in principle contribute to comedogenicity at high concentrations on acne-prone skin. At the 0.5–2% formulation range typical for Pal-AHK products, comedogenic risk is low but not zero. Acne-prone users should monitor for follicular plugging, particularly with leave-on facial products.
• Lack of systemic safety data — There is no published systemic toxicology data on Pal-AHK. The molecule has not been tested in oral, parenteral, or inhalation toxicology studies — it has been evaluated only as a topical cosmetic ingredient. Off-label systemic use is not supported by any safety evidence.
• No documented drug-drug interactions — Topical Pal-AHK does not have documented interactions with oral or topical pharmaceuticals at typical cosmetic concentrations. Theoretical interactions with topical retinoids (potential additive irritation), topical corticosteroids (no documented mechanism), or scalp minoxidil (commonly co-applied without reported interaction) have not been formally evaluated in controlled studies.
• Pregnancy and lactation — Standard cosmetic-pregnancy guidance applies. Topical cosmetic peptides at low concentrations have not been associated with adverse pregnancy outcomes, but safety data specific to Pal-AHK in pregnancy or lactation is absent. Users who are pregnant or nursing should consult their obstetric or pediatric clinician before initiating any new topical regimen.
• Pediatric use — Not formulated for or studied in pediatric populations. Adult cosmetic use only.
• Eye area — Periorbital application is acceptable in well-formulated eye creams; avoid direct ocular contact. Flush with water if accidental eye exposure occurs.
• Open / broken skin — Avoid application on actively bleeding wounds, surgical incisions, or extensive open dermatitis. Microneedling adjunct use should follow clinician guidance and standard infection-control practice; the cosmetic vehicle is not sterile and the peptide-vehicle combination is not a wound dressing.
• WADA status — Topical cosmetic Pal-AHK is not specifically listed on the World Anti-Doping Agency Prohibited List. Athletes using cosmetic skincare products should not encounter testing concerns from typical topical use, but should consult sport-specific anti-doping resources for any competitive context.
• Cross-reactivity with copper-allergic individuals — Notable: a small subset of consumers report contact dermatitis to copper peptides (GHK-Cu, AHK-Cu). For those individuals, a copper-free Pal-AHK product is one of the rationales for choosing the lipidated form. The peptide backbone itself has not been associated with a recognized contact-allergy syndrome at cosmetic concentrations.

Bloodwork & Monitoring

Pal-AHK is a topical cosmetic ingredient. There is no recognized bloodwork or laboratory-monitoring protocol for typical cosmetic use, and routine clinical monitoring is not warranted for individuals applying a Pal-AHK serum or cream as part of a daily skincare or hair-care regimen.

• No routine laboratory monitoring — Topical peptide cosmetics at standard formulation percentages do not generate measurable systemic exposure that would justify CBC, CMP, hormonal panel, or specialty bloodwork. The penetration data for palmitoyl peptides indicates dermal accumulation with negligible systemic absorption (CIR safety assessment of palmitoyl oligopeptides).
• Patch testing for new users — Standard cosmetic patch test on a small skin area (inner forearm or postauricular) for 48–72 hours before broader application is reasonable for individuals with sensitive skin, prior peptide reactions, or extensive cosmetic contact allergy history.
• Photographic monitoring (cosmetic outcomes only) — For users applying Pal-AHK as part of a hair-growth or skin-firming regimen, consistent baseline-and-follow-up photography under matched lighting and angle conditions is the most useful self-assessment tool. Subjective improvement reports are highly susceptible to confirmation bias without controlled photography.
• Dermatologist follow-up if scalp use — For users adding Pal-AHK as part of a hair-loss treatment regimen, a baseline dermatology consultation to characterize the underlying alopecia (androgenetic, telogen effluvium, alopecia areata, traction, scarring) is prudent. Cosmetic peptides are not a substitute for diagnostic workup or for evidence-based pharmacologic interventions (topical minoxidil, oral or topical finasteride / dutasteride under clinical supervision, oral spironolactone in appropriate patients) where indicated.
• No required imaging or specialty testing — Topical cosmetic peptide use does not warrant scalp ultrasound, dermoscopy, trichoscopy, or trichogram outside the routine dermatologic workup of the underlying hair condition.

Commonly Stacked With

Pal-AHK is most often formulated alongside other cosmetic peptides and ancillary actives in multi-ingredient hair-growth scalp serums and skin-firming facial products. Common pairings:

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Lipidated tripeptide cousins in the palmitoyl family:

Next Steps

Key References

1. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. doi:10.1007/BF02978833. PMID: 17703734. (The single most-cited primary study for the AHK sequence in any hair-growth context. AHK-Cu²⁺ at 10⁻¹² to 10⁻⁹ M stimulated proliferation of cultured human dermal papilla cells, reduced apoptosis, increased VEGF expression, and elongated ex-vivo human hair follicles. The agent tested was the copper-bound complex, not Pal-AHK.)
2. Pickart L, Thaler MM. A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochem Biophys Res Commun. 1973;54(2):562-566. doi:10.1016/0006-291x(73)91459-9. PMID: 4356974. (The original Pickart hepatocyte tripeptide paper that launched the GHK / AHK tripeptide-copper field.)
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. (Comprehensive 2018 transcriptomic review of GHK and GHK-Cu effects on human gene expression. Frequently cited by Pal-AHK marketing as evidence for "gene modulation" claims; the underlying data is for GHK / GHK-Cu, not for AHK or Pal-AHK.)
4. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Biomed Res Int. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519. (Review of the human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging; provides historical context for the tripeptide-copper class.)
5. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18047928. (Comprehensive review of the GHK / GHK-Cu literature including wound healing, hair-transplant survival, and gene-expression effects. Establishes the framework within which the AHK literature is interpreted.)
6. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (Categorizes cosmetic peptides into signal, neurotransmitter-affecting, and carrier classes. Frames the rationale for palmitoylation as a delivery strategy. Foundational cosmetic-peptide review.)
7. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (Open-access review covering pal-KTTKS, palmitoyl tripeptide-1 / -3 / -5, palmitoyl-β-Ala-His, and others, with clinical-study citations and mechanistic discussion of palmitoyl-peptide skin penetration.)
8. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492182. (12-week double-blind placebo-controlled split-face RCT in 93 women applying 3 ppm pal-KTTKS in moisturizer; significant improvement in fine lines and wrinkles versus moisturizer alone. The methodological template for what a real palmitoyl-peptide cosmetic RCT looks like.)
9. Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. doi:10.4062/biomolther.2014.053. PMID: 25143811. (Confirms that palmitoylation increases skin permeation and dermal stability of the parent peptide; mechanistically informative for the palmitoyl-peptide class as a whole.)
10. Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel). 2021;14(8):702. doi:10.3390/ph14080702. PMID: 34451799. (Analysis of 88 facial cosmetics for sensitive skin, showing that palmitoyl tripeptide-8, palmitoyl tripeptide-5, palmitoyl tetrapeptide-7, and palmitoyl oligopeptide are commonly used in marketed products. Useful context for where the palmitoyl-tripeptide family sits in the contemporary cosmetic ingredient landscape.)
11. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. doi:10.3389/fchem.2020.572923. (Modern review of cosmeceutical peptides including the GHK / AHK family in the context of cosmetic regulatory frameworks and sustainability; cites Lupo & Cole and the broader signal-peptide literature.)
12. Ferreira MS, Magalhães MC, Sousa-Lobo JM, Almeida IF. Trending Anti-Aging Peptides. Cosmetics. 2020;7(4):91. doi:10.3390/cosmetics7040091. (Open-access review of the cosmetic peptide field; catalogues the palmitoyl tripeptide family on INCI lists of marketed products.)
13. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. doi:10.1111/j.1468-2494.2009.00490.x. PMID: 19570099. (Foundational review of topical peptides in aging-skin applications; covers GHK-Cu, pal-KTTKS, palmitoyl-Gly-His-Lys, and related compounds with mechanism and clinical-evidence discussion.)
14. Aldag C, Nogueira Teixeira D, Leventhal PS. Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literature. Clin Cosmet Investig Dermatol. 2016;9:411-419. doi:10.2147/CCID.S116158. PMID: 27877059. (Cosmetic-dermatology review of growth-factor and matrikine peptide products with discussion of palmitoyl peptide class.)
15. Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics. CIR Final Report. 2012. Available at cir-safety.org. (Industry-standard safety assessment of the palmitoyl oligopeptide class, including discussion of skin penetration, irritation, sensitization, and acute and repeated-dose toxicology data gaps. Pal-AHK falls within the scope of this class assessment.)
16. Lima TN, Moraes CAP. Bioactive Peptides: Applications and Relevance for Cosmeceuticals. Cosmetics. 2018;5(1):21. doi:10.3390/cosmetics5010021. (Open-access review of bioactive peptides in cosmeceutical applications; covers signal-peptide, carrier-peptide, and neurotransmitter-affecting peptide classes.)